Orchard licenses gene therapy tech from GSK

Orchard licenses gene therapy tech from GSK

Source: 
Fierce Biotech
snippet: 

Orchard Therapeutics has licensed lentiviral stable cell line technology from GlaxoSmithKline for use in its hematopoietic stem cell gene therapies. GSK filed for patents on the technology before selling its rare disease gene therapy portfolio to Orchard in 2018.